Healthcare Industry News: lipopeptide
News Release - August 9, 2007
Theratechnologies Appoints Dr. Pierre Caudrelier as Chief Medical OfficerMONTREAL, QUEBEC--(Healthcare Sales & Marketing Network)--Aug 9, 2007 -- Theratechnologies (Toronto:TH.TO ) today announced the appointment of Pierre Caudrelier, M.D., as Chief Medical Officer. This appointment will take effect in early September, 2007.
Dr. Caudrelier spent most of his career working in clinical research and development of HIV products such as: live recombinant viral vectors, recombinant proteins, and lipopeptides in both prophylactic and therapeutic indications. He has been involved in all aspects of clinical development (Phase 1-4) in HIV products including the interaction with regulatory bodies and international agencies worldwide including Europe and North America. Experienced in the area of immunology and immunotherapies, Dr. Caudrelier has led the development for cell-based immunotherapies and vaccines during his career.
For over 15 years, Dr. Caudrelier held various positions at Aventis Pasteur (now Sanofi Aventis) ending his career there in the position of Clinical Program Director, HIV Program. In this role he was responsible for clinical development of certain HIV products and, at the time of his departure, was responsible for over 40 clinical trials including the preparation of two large Phase 3 trials in Thailand and the Americas.
Dr. Caudrelier was recently Vice President, Clinical Research & Chief Medical Officer at Kiadis Pharma where he led the clinical development on four proprietary products in the area of oncology. Previously, Dr. Caudrelier was at Immuno-Designed Molecules (I.D.M. Biotech) as Vice President, Scientific and Medical Affairs where he equally led the clinical research and development aspects for this company.
"Dr. Caudrelier's vast knowledge in clinical research and development will contribute significantly to the completion of TH9507 in HIV-associated lipodystrophy as well as in choosing a second indication for TH9507 by year end," noted Mr. Yves Rosconi, President and Chief Executive Officer of Theratechnologies. "Having worked for almost a decade internationally in the HIV arena, Dr. Caudrelier has both the regulatory and clinical expertise to lead our clinical team towards the final stages of development of TH9507 in lipodystrophy. I would like to take this opportunity to welcome Dr. Caudrelier to the Theratechnologies team," commented Mr. Rosconi.
Dr. Caudrelier has a medical doctorate from the University of Paris VI, Pitie-Salpetriere Hospital and an Inter-Universitary Diploma of Applied Epidemiology at the Universities of Tours & Bordeaux II.
Theratechnologies (Toronto:TH.TO ) is a Canadian biopharmaceutical company that discovers or acquires innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is TH9507, now in a second confirmatory Phase 3 clinical trial for a serious metabolic disorder known as HIV-associated lipodystrophy. The Company also has other projects at earlier stages of development.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.